Intellia's three-year HAE treatment data shows durability, Citizens JMP says

Citizens JMP maintained a Market Perform rating on Intellia Therapeutics (NTLA) after positive three-year data from its Phase I trial of Lonvo-z for hereditary angioedema (HAE) was presented at the EAACI conference, showing a 98% reduction in attack rates. While H.C. Wainwright reiterated a Buy rating with a $30 target, other firms adjusted price targets, with Canaccord Genuity lowering its target to $54 from $74 due to revised timelines for the ATTR-CM program, and Cantor Fitzgerald maintaining an Overweight rating with a $65 price target despite a Grade 4 liver enzyme elevation reported in the Phase 3 MAGNITUDE study, which they believe is an overreaction.

Analysis

Intellia Therapeutics (NTLA) reported encouraging three-year follow-up data for Lonvo-z (NTLA-2002) in hereditary angioedema (HAE), showcasing a 98% reduction in attack rates and a median attack-free period of 23 months, underscoring the treatment's durability. Despite these positive clinical results, Citizens JMP maintained a Market Perform rating, asserting the stock, trading at $8.96, is "fairly valued" based on their discounted cash flow analysis. This stance contrasts with other analysts: H.C. Wainwright reiterated a Buy rating ($30 target), while Canaccord Genuity adjusted its target to $54 (from $74) due to revised ATTR-CM program launch timelines, though still projecting $4 billion peak sales by 2035. Bernstein SocGen Group (Outperform, $45 target) and Cantor Fitzgerald (Overweight, $65 target) remained bullish despite recent Grade 4 adverse events—a liver enzyme elevation in the Phase 3 MAGNITUDE study and another unspecified event—with Cantor Fitzgerald deeming the market's negative reaction to the liver enzyme issue an overreaction and H.C. Wainwright noting this issue was resolving. The stock's significant 52-week trading range of $5.90 to $28.18 highlights market sensitivity to clinical developments and varying analyst interpretations of their impact.

Key Decisions for Investors

• Investors should acknowledge the strong long-term clinical efficacy data for Lonvo-z but balance this against the mixed analyst ratings and revised program timelines which contribute to NTLA's current valuation and significant stock volatility.
• Close monitoring of further data releases, particularly concerning the full resolution and context of reported adverse events from ongoing trials like MAGNITUDE, and progress on the ATTR-CM program's launch, is critical given their direct impact on analyst price targets and overall sentiment.
• Given NTLA's substantial stock price fluctuations and the wide dispersion in analyst valuations, investors should carefully assess their risk tolerance and consider whether the current price adequately reflects both the high potential of its gene editing platform and the inherent development risks, including safety signals and timeline adjustments.